September 14, 2020 -- GlycoT Therapeutics has signed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo.
The agreement grants Daiichi Sankyo worldwide and nonexclusive rights to intellectual property that GlycoT currently licenses from the University of Maryland, Baltimore and University of Maryland, College Park. The deal includes an undisclosed upfront payment, annual fees, and royalties on sales of GlycoT.
The enzymatic glycoengineering technology platform allows scientists to precisely change and modify the sugars on monoclonal antibodies. Daiichi Sankyo plans to use the technology in the development of new drug candidates.
The technology was originally developed by Lai-Xi Wang, PhD, founder and president of GlycoT Therapeutics and professor in the department of chemistry and biochemistry at the University of Maryland, College Park.
Copyright © 2020 scienceboard.net